Market Overview

New Patent for Adipose Stem Cells Issued to VetStem Biopharma

Share:

VetStem Biopharma issued patent that covers methods for extracting/preparing and using adipose tissue-derived stem cells for musculoskeletal injury in any mammal, including humans.

POWAY, Calif. (PRWEB) July 31, 2018

Leading regenerative veterinary medicine company, VetStem Biopharma, has been issued a major patent that covers methods for extracting and using adipose tissue-derived stem cells to treat or prevent inflammation at the site of musculoskeletal injury in any mammal, including humans. While this patent covers Canada specifically, VetStem has been issued similar patents that cover the United States as well as the EU.

The new patent adds to VetStem's patent portfolio that covers methods of using regenerative cells from adipose tissue in humans and animals. CEO and VetStem founder, Dr. Bob Harman, believes these patents are an important way to strengthen the company's intellectual property in the rapidly developing field of regenerative medicine.

As the first company to provide adipose derived stem cell services to veterinarians in the United States and Canada, VetStem has quickly developed the market. With over 13,000 animals treated, Dr. Harman believes it is crucial to take appropriate actions to protect the market they are developing and to optimize the value of the company. Dr. Harman stated, "We have invested heavily in patent protection of our technology and we have engaged appropriate counsel to work with companies interested in licensing our technology for commercial use."

As stem cell therapy becomes more widely recognized and utilized in both veterinary and human medicine, VetStem strives to stay at the forefront of the field. They continue to explore non-standard uses for stem cells such as organ failure and immune-mediated diseases. The VetStem R&D team are also in the process of developing an off-the-shelf "donor-derived" stem cell product for arthritis in canines and additional products for use in feline and equine disease therapy. VetStem has three Investigational New Animal Drug applications filed with the FDA.

About VetStem Biopharma, Inc.
VetStem Biopharma is a veterinarian-lead Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients' own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 13,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The Company's stated mission being "to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases". In addition to its' own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 70 issued patents in the field of regenerative medicine.

For the original version on PRWeb visit: https://www.prweb.com/releases/new_patent_for_adipose_stem_cells_issued_to_vetstem_biopharma/prweb15661247.htm

View Comments and Join the Discussion!